David Baratz, MD
Pulmonary Disease · Phoenix, AZNPI 1104879436
Payments from drug & device makers
Across 1,067 payments — averaging $2022.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.1M
- Kadmon Corporation LLC$907K
- Novartis$46K
- Acceleron Pharma, Inc.$26K
- Sanofi US Services Inc.$17K
- Actelion Pharmaceuticals US, Inc.$10K
- plus $26K from 54 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,158,363 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Phoenix
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Mark GotfriedPhoenix$1.1M
- Abid KhokarPhoenix$321K
- Brian PorvinPhoenix$276K
- Tony HodgesPhoenix$262K
- Rajeev SaggarPhoenix$219K
- Ali SaeedPhoenix$213K
- Bhuvin BuddhdevPhoenix$202K
- Gregory AhearnPhoenix$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.